Opportunity Information: Apply for TI 18 009
The Medication Assisted Treatment - Prescription and Opioid Addiction (MAT-PDOA) grant opportunity (Funding Opportunity Number TI 18 009) is a discretionary grant program offered by the U.S. Department of Health and Human Services through SAMHSA's Center for Substance Abuse Treatment. Released on May 9, 2018 with an application deadline of July 9, 2018, it was designed to expand and strengthen access to medication-assisted treatment (MAT) for people diagnosed with opioid use disorder (OUD), especially individuals who are seeking MAT or already receiving it but need improved availability, continuity, or supporting services.
A central feature of this opportunity is its targeted approach. Rather than being broadly distributed across all states, the program prioritizes funding for organizations and tribes or tribal organizations operating in states identified by SAMHSA as having the highest per-capita rates of treatment admissions for heroin and opioid use, along with states that experienced the sharpest increases in those admissions. Those priority determinations were based on SAMHSA's 2015 Treatment Episode Data Set (TEDS), meaning the funding strategy is tied to documented treatment-need indicators and rapid growth trends in opioid-related admissions.
The program requires that grantees provide MAT using at least one FDA-approved medication for maintenance treatment of OUD. The allowable and explicitly referenced medications include methadone; buprenorphine and buprenorphine/naloxone products (such as sublingual tablets or films, buccal film, and extended-release, long-acting injectable buprenorphine formulations); and injectable naltrexone. In other words, this is not a general opioid services grant where medication can be optional; medication treatment is a mandatory core activity, and proposals are expected to directly increase the capacity to deliver these evidence-based pharmacotherapies.
At the same time, the grant is not limited to prescribing medication alone. SAMHSA emphasizes that MAT must be delivered alongside comprehensive psychosocial and recovery-oriented supports that address the broader clinical and social needs that often drive relapse risk and treatment dropout. The opportunity highlights services such as counseling and behavioral therapies, Recovery Support Services (RSS), and other clinically appropriate supports needed to help individuals achieve and maintain abstinence from opioids. This reflects a whole-person treatment expectation: medication to stabilize cravings and withdrawal, plus structured therapeutic and recovery supports to improve functioning, retention, and long-term outcomes.
The intended outcomes are framed around measurable improvements in treatment access and opioid-use behaviors. The grant aims to increase the number of individuals with OUD who receive MAT and to reduce illicit opioid use and prescription opioid misuse at a six-month follow-up point. This outcome structure signals that applicants are expected to track service delivery and patient outcomes over time, demonstrating not just that more people were served, but that treatment is associated with meaningful reductions in harmful opioid use.
From a funding standpoint, the program listed an award ceiling of $524,670 and anticipated making about 125 awards. The funding activity category is health (CFDA 93.243). Eligibility is noted as "Others (see text field entitled Additional Information on Eligibility for clarification)," indicating that eligible applicants extend beyond a single standard category and may include a variety of organizational types, with a specific emphasis on organizations and tribal entities working in the identified high-need states.
Overall, MAT-PDOA is best understood as a capacity-expansion initiative focused on rapidly increasing access to proven medications for OUD in the jurisdictions hit hardest by heroin and opioid-related treatment admissions, while requiring that medication treatment be integrated with counseling, behavioral health interventions, and recovery supports to improve retention and reduce opioid misuse over time.Apply for TI 18 009
- The Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis in the health sector is offering a public funding opportunity titled "Medication Assisted Treatment – Prescription and Opioid Addiction" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.243.
- This funding opportunity was created on May 09, 2018.
- Applicants must submit their applications by Jul 09, 2018. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $524,670.00 in funding.
- The number of recipients for this funding is limited to 125 candidate(s).
- Eligible applicants include: Others (see text field entitled Additional Information on Eligibility for clarification).
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
MAT-PDOA (TI 18 009) Grant Opportunity FAQs
1) What is the MAT-PDOA grant (Funding Opportunity Number TI 18 009)?
The Medication Assisted Treatment - Prescription and Opioid Addiction (MAT-PDOA) opportunity (Funding Opportunity Number TI 18 009) is a discretionary grant program from the U.S. Department of Health and Human Services (HHS) through SAMHSA's Center for Substance Abuse Treatment. It was designed to expand and strengthen access to medication-assisted treatment (MAT) for people diagnosed with opioid use disorder (OUD).
2) Which federal agency is offering this funding?
This opportunity is offered by HHS through the Substance Abuse and Mental Health Services Administration (SAMHSA), specifically SAMHSA's Center for Substance Abuse Treatment.
3) When was the opportunity released and when were applications due?
The opportunity was released on May 9, 2018, and the application deadline was July 9, 2018.
4) What problem is this grant intended to address?
The grant is intended to improve access to evidence-based treatment for opioid use disorder by expanding capacity to deliver medication-assisted treatment. It focuses on improving availability, continuity, and supporting services for people seeking MAT or already receiving MAT.
5) Who is the target population for services supported by this grant?
The focus is on people diagnosed with opioid use disorder (OUD), especially individuals who are seeking MAT or who are already receiving MAT but need improved availability, continuity, or supporting services.
6) Is this funding distributed broadly across all states?
No. This opportunity uses a targeted approach that prioritizes organizations and tribes or tribal organizations operating in states identified by SAMHSA as having the highest per-capita rates of treatment admissions for heroin and opioid use, as well as states with the sharpest increases in those admissions.
7) How did SAMHSA determine which states are considered priority states?
Priority determinations were based on SAMHSA's 2015 Treatment Episode Data Set (TEDS), focusing on (1) states with the highest per-capita treatment admission rates for heroin and opioid use and (2) states that experienced the largest increases in those admissions.
8) What is the central program requirement for funded projects?
A core requirement is that grantees provide medication-assisted treatment using at least one FDA-approved medication for maintenance treatment of opioid use disorder. Medication treatment is not optional under this opportunity.
9) Which medications are explicitly referenced as allowable for MAT under this grant?
The opportunity explicitly references methadone; buprenorphine and buprenorphine/naloxone products (including sublingual tablets or films, buccal film, and extended-release, long-acting injectable buprenorphine formulations); and injectable naltrexone.
10) Can an applicant propose an opioid services program without medication as the core activity?
No. This is not described as a general opioid services grant where medication can be optional. Proposals are expected to directly increase capacity to deliver evidence-based pharmacotherapies for OUD.
11) Does SAMHSA expect services beyond prescribing medication?
Yes. SAMHSA emphasizes that MAT should be delivered alongside comprehensive psychosocial and recovery-oriented supports that address broader clinical and social needs that can contribute to relapse risk and treatment dropout.
12) What types of supportive services are highlighted as part of a comprehensive approach?
The opportunity highlights counseling and behavioral therapies, Recovery Support Services (RSS), and other clinically appropriate supports needed to help individuals achieve and maintain abstinence from opioids.
13) What overall treatment model is SAMHSA emphasizing in this opportunity?
The opportunity reflects a whole-person treatment expectation: medication to help stabilize cravings and withdrawal, combined with structured therapeutic and recovery supports to improve functioning, retention, and long-term outcomes.
14) What outcomes is the MAT-PDOA program intended to achieve?
The intended outcomes include increasing the number of individuals with OUD who receive MAT and reducing illicit opioid use and prescription opioid misuse at a six-month follow-up point.
15) Are applicants expected to measure outcomes over time?
Yes. The opportunity frames outcomes around measurable improvements in access and opioid-use behaviors, including changes observed at a six-month follow-up, indicating that applicants are expected to track service delivery and patient outcomes over time.
16) How many awards were anticipated under this opportunity?
The program anticipated making about 125 awards.
17) What was the maximum (ceiling) award amount?
The listed award ceiling was $524,670.
18) What is the funding activity category and CFDA number associated with this opportunity?
The funding activity category is health, and the CFDA number listed is 93.243.
19) Who is eligible to apply?
Eligibility is listed as "Others (see text field entitled Additional Information on Eligibility for clarification)." Based on the description provided, eligible applicants extend beyond a single standard category and may include a variety of organizational types, with specific emphasis on organizations and tribal entities working in identified high-need states.
20) Are tribes and tribal organizations specifically relevant to this funding?
Yes. The opportunity specifically prioritizes funding for organizations and tribes or tribal organizations operating in SAMHSA-identified high-need states.
21) What does "capacity expansion" mean in the context of this grant?
Based on the opportunity description, the grant is positioned as a capacity-expansion initiative focused on rapidly increasing access to proven medications for OUD, particularly in jurisdictions with the highest or fastest-growing opioid-related treatment admissions.
22) What does "continuity" of MAT refer to in this opportunity?
The opportunity emphasizes improving availability and continuity for people seeking MAT or already receiving it. In this context, continuity refers to maintaining access to MAT and related supports over time rather than having interruptions in care.
23) Is the focus limited to heroin, or does it include prescription opioid misuse as well?
It includes both. Priority state identification is tied to treatment admissions for heroin and opioid use, and intended outcomes include reductions in illicit opioid use and prescription opioid misuse.
24) How would you summarize the purpose of MAT-PDOA in one sentence?
MAT-PDOA is designed to expand access to FDA-approved medications for opioid use disorder in the hardest-hit jurisdictions while requiring that medication treatment be integrated with counseling, behavioral interventions, and recovery supports to improve retention and reduce opioid misuse over time.
Browse more opportunities from the same category: Health
Next opportunity: Diabetes and Heart Disease & Stroke Prevent Programs-Innovative State and Local Public Health Strategies to Prevent and Manage Diabetes and Heart Disease and Stroke
Previous opportunity: Maternal, Infant, and Early Childhood Home Visiting Program - Formula
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for TI 18 009
Applicants also applied for:
Applicants who have applied for this opportunity (TI 18 009) also looked into and applied for these:
| Funding Opportunity |
|---|
| Diabetes and Heart Disease & Stroke Prevent Programs-Innovative State and Local Public Health Strategies to Prevent and Manage Diabetes and Heart Disease and Stroke Apply for CDC RFA DP18 1817 Funding Number: CDC RFA DP18 1817 Agency: Department of Health and Human Services, Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $3,000,000 |
| Evidence-Based Tele-Behavioral Health Network Program Apply for HRSA 18 032 Funding Number: HRSA 18 032 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| National Population-based HIV Impact Assessment (PHIA) in Nigeria under the Presidents Emergency Plan for AIDS Relief (PEPFAR) Apply for CDC RFA GH18 18130101SUPP18 Funding Number: CDC RFA GH18 18130101SUPP18 Agency: Department of Health and Human Services, Centers for Disease Control - CGH Category: Health Funding Amount: $32,847,356 |
| Improved Health for Underserved Filipinos Apply for 72049218APS00001 Funding Number: 72049218APS00001 Agency: Agency for International Development, Philippines USAID-Manila Category: Health Funding Amount: $49,000,000 |
| Certified Community Behavioral Health Clinic Expansion Grants Apply for SM 18 019 Funding Number: SM 18 019 Agency: Department of Health and Human Services, Substance Abuse and Mental Health Services Adminis Category: Health Funding Amount: $2,000,000 |
| Research Program Award (R35 Clinical Trial Optional) Apply for RFA NS 18 032 Funding Number: RFA NS 18 032 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $750,000 |
| Racial and Ethnic Approaches to Community Health (REACH) Apply for CDC RFA DP18 1813 Funding Number: CDC RFA DP18 1813 Agency: Department of Health and Human Services, Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $900,000 |
| NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional) Apply for RFA HL 19 018 Funding Number: RFA HL 19 018 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional) Apply for RFA HL 19 017 Funding Number: RFA HL 19 017 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $1,000,000 |
| Limited Competition: Cardiothoracic Surgical Trials Network (CTSN) Data Coordinating Center (U01 Clinical Trial Required) Apply for RFA HL 19 010 Funding Number: RFA HL 19 010 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: Case Dependent |
| Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers (UM1 Clinical Trial Not Allowed ) Apply for RFA HL 19 009 Funding Number: RFA HL 19 009 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: $400,000 |
| ARC Congressional Grant Apply for HQ0034 18 1 0002 Funding Number: HQ0034 18 1 0002 Agency: Department of Defense Category: Health Funding Amount: $24,000,000 |
| ARMM Health Capacity Building Activity Apply for 72049218APS00001 02 Funding Number: 72049218APS00001 02 Agency: Agency for International Development, Philippines USAID-Manila Category: Health Funding Amount: $16,000,000 |
| RISE II HEALTH SERVICES DELIVERY ACTIVITY Apply for RFI 625 18 RISEII HSD Funding Number: RFI 625 18 RISEII HSD Agency: Agency for International Development, Senegal USAID-Dakar Category: Health Funding Amount: Case Dependent |
| Vulnerable Rural Hospitals Assistance Program Apply for HRSA 18 121 Funding Number: HRSA 18 121 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| Diabetes and Heart Disease & Stroke Prevent Programs-Improving the Health of Americans through Prevention and Management of Diabetes and Heart Disease and Stroke Apply for CDC RFA DP18 1815 Funding Number: CDC RFA DP18 1815 Agency: Department of Health and Human Services, Centers for Disease Control - NCCDPHP Category: Health Funding Amount: $3,000,000 |
| Community-Based Violence Prevention and Linkages to Response in South Africa Apply for 72067418RFA00008 Funding Number: 72067418RFA00008 Agency: Agency for International Development, South Africa USAID-Pretoria Category: Health Funding Amount: $19,800,000 |
| Health Financing Improvement Program Apply for 72066318RFA00001 Funding Number: 72066318RFA00001 Agency: Agency for International Development, Ethiopia USAID-Addis Ababa Category: Health Funding Amount: $40,000,000 |
| Expansion of the Family-to-Family Health Information Centers Apply for HRSA 18 115 Funding Number: HRSA 18 115 Agency: Department of Health and Human Services, Health Resources and Services Administration Category: Health Funding Amount: Case Dependent |
| NIH Directors Transformative Research Award (R01 - Clinical Trial Optional) Apply for RFA RM 18 009 Funding Number: RFA RM 18 009 Agency: Department of Health and Human Services, National Institutes of Health Category: Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "TI 18 009", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.